Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of April 2019, with the report dated April 15, 2019. The filing primarily serves to incorporate a press release regarding a commercial milestone for the Company's product, Namodenoson.
Key Financial Metrics
The filing reports a specific cash inflow event but does not provide comprehensive financial statements for the period.
- Revenue/Cash Inflow: The Company received a payment of $1,000,000 from Chong Kun Dang Pharmaceuticals (CKD).
- Transaction Context: The payment relates to the distribution of Namodenoson in South Korea.
- Other Metrics: The filing text does not provide clear values for net profit, operating margins, total debt, or overall liquidity positions for the period.
Material Changes
The primary material change disclosed is the receipt of the $1,000,000 payment from CKD on April 10, 2019. This represents a significant commercial development for the Company's South Korean distribution agreement. No comparative financial data or year-over-year changes are provided in this specific filing.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference into the Company's Registration Statements on Form S-8 and Form F-3. However, the text of this Form 6-K does not explicitly detail specific future guidance, quantitative outlooks, or a list of material risks and contingencies beyond the standard incorporation by reference.
Investor Verification Checklist
- Verify the full text of the press release dated April 15, 2019 (Exhibit 99.1) for detailed terms of the CKD agreement.
- Review the incorporated "Forward Looking Statements" in the referenced Registration Statements (File Nos. 333-227753, 333-195124, 333-204795, 333-209037, and 333-220644) for risk factors and future projections.
- Confirm the impact of the $1,000,000 payment on the Company's overall cash position by reviewing the most recent audited financial statements or quarterly reports.